Frequently Asked Questions

What are the primary toxicology concerns for prime editor systems?

The main areas of investigation include off-target editing events, potential immunogenicity against the nuclease and pegRNA components, biodistribution and persistence of the editing machinery, and any long-term genotoxicity resulting from unintended genomic alterations.

How does the delivery system affect the toxicology strategy?

The delivery vehicle (e.g., Lipid Nanoparticles or AAV vectors) dictates a significant portion of the safety assessment. An LNP-based approach requires evaluation of the lipid components’ toxicity and inflammatory potential, while a viral vector approach necessitates a focus on capsid immunogenicity, vector shedding, and integration potential.

Why is a standard toxicology package insufficient for prime editors?

Prime editors operate with a distinct mechanism that minimizes double-stranded breaks, leading to a different off-target profile compared to traditional nucleases like Cas9. A generic toxicology plan fails to adequately address the unique guide RNA requirements, potential for reverse transcriptase activity, and the specific off-target signatures inherent to this technology.

Additional Insights

A tailored preclinical strategy is fundamental to evaluating the safety of advanced therapeutics and complex biologics. For novel gene editing systems like prime editors, applying proven intelligence in IND-enabling toxicology is necessary to accelerate these next-generation therapies toward regulatory submission. A predefined template approach is inadequate for characterizing the unique risk profile of these precise editing platforms.

The design of a relevant safety program begins with the scientific rationale of the therapeutic. This involves a deep assessment of the editing components, the delivery system, and the target indication. The transition from a controlled discovery environment to a complex biological system demands a bespoke study design that anticipates and measures potential liabilities.

Selecting the most relevant biological system for preclinical evaluation is a pivotal decision. Biodistribution studies often reveal significant cross-species differences that directly influence safety and efficacy outcomes, a principle observed in vector engineering research (PMID: 39001819). The goal is to utilize systems that provide the most predictive data on immunological and physiological responses relevant to human biology.

This methodical approach aligns with a core principle of responsible research. Dr. Naageshwaran reinforces this: “We have to do animal research, so let’s do it well. Let’s do it right the first time, right? The most important thing is to do it right the first time so you’re not using any more animals than you’re absolutely required to.” A well-designed study under GLP conditions generates definitive data. This approach supports the track record of our scientific leadership, who have maintained a 100% successful IND rate since 2019, now continuing under the Franklin Biolabs brand launched in 2024.

A robust IND-enabling program for prime editors includes several key evaluations:

• Off-Target Nomination: In-silico prediction followed by in vitro screening to identify the most probable off-target sites for subsequent evaluation in relevant biological systems.
• Biodistribution & Persistence: Quantifying the distribution and clearance of the editor and guide RNA components in target and off-target tissues.
• Immunogenicity: Development of phase-appropriate, GCLP-compliant assays to measure humoral and cellular immune responses to the editing system.
• GLP Toxicology: Pivotal toxicology studies to establish a safety profile and determine the proposed clinical exposure levels.

This data-driven preclinical strategy provides the comprehensive safety package required for regulatory review and minimizes clinical risk for novel gene editing therapeutics.

Learn more about our approach to Preclinical | Translational Services.